De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive oropharyngeal carcinoma

. 2018 Dec 14;2018(12):CD012939. doi: 10.1002/14651858.CD012939.pub2

Study	Reason for exclusion
EORTC‐1420	ALLOCATION: prospective randomised controlled trial PARTICIPANTS: HPV‐positive OPSCC INTERVENTION: minimally invasive (endoscopic) head and neck surgery versus standard radiotherapy ± adjuvant chemotherapy (non‐surgical, therefore excluded)
ORATOR	ALLOCATION: prospective randomised controlled trial PARTICIPANTS: HPV‐positive OPSCC INTERVENTION: minimally invasive (endoscopic) head and neck surgery versus standard radiotherapy ± adjuvant chemotherapy (non‐surgical, therefore excluded)

HPV: human papillomavirus  OPSCC: oropharyngeal squamous cell cancer